Join
Live feed
·
PRReleasevia Quantisnow
IGC Pharma Inc. logo

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
IGC· IGC Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IGC (IGC Pharma Inc.) and more on Quantisnow.